Trend-Following Backtester · Guide · backtest 한국어

equity · US

Crinetics Pharmaceuticals, Inc. backtest

10 trend-following strategies were compared on the full daily history of Crinetics Pharmaceuticals, Inc.. 0 beat buy-and-hold CAGR; MACD ranks first by Sharpe, matching the main backtester.

Data 2018-07-18 ~ 2026-07-31daily bars 2,020 (8.0 years)Costs 0.5%Venue XNASMonthly snapshot 2026-07-31

Results by strategy

0 of 10 beat buy and hold (CAGR 16.4%, drawdown -68.7%).

Sharpe leader (same as main): MACD — CAGR 7.7%, MDD -72.1%, Sharpe 0.37, 53% exposure.

No strategy retained at least 75% of buy-and-hold CAGR while reducing drawdown by both 20% relatively and 5 percentage points absolutely.

The alternative must retain 75% of buy-and-hold CAGR, improve drawdown by at least 20% and 5 percentage points, and stay below 95% exposure; the ranking weights return retention 60% and drawdown improvement 40%.

Strategy · parametersCAGRMDDSharpeCalmarTotalTradesExposure
MACD
fast=17, slow=30, signal=18
7.7%-72.1%0.370.111.8x9153%
Donchian 채널 돌파
entryN=21, exitN=23
6.0%-67.1%0.340.091.6x3351%
ADX / DI 방향성
period=35, threshold=14
6.0%-53.6%0.340.111.6x3332%
Keltner 채널 돌파
emaPeriod=58, atrPeriod=36, mult=2.3
4.9%-66.0%0.280.071.5x2928%
EMA 크로스오버
fast=8, slow=49
2.6%-75.9%0.270.031.2x5749%
Parabolic SAR
step=0.02, maxStep=0.2
1.8%-76.1%0.270.021.2x17753%
볼린저 밴드 돌파
n=25, k=3.2
5.1%-35.8%0.260.141.5x157%
Supertrend
period=15, mult=2.9
1.1%-72.0%0.250.021.1x4750%
ROC 모멘텀
n=72, threshold=-0.01
0.2%-83.2%0.230.001.0x10954%
SMA 크로스오버
fast=49, slow=123
-6.7%-70.2%0.02-0.100.6x1948%
Buy and hold16.4%-68.7%0.530.243.4x1100%
1x 2019 2020 2021 2022 2023 2024 2025 2026 MACDBuy and hold
MACD: Solid strategy line versus dashed buy-and-hold line. Log scale.
0% -18% -36% -54% -72% 2019 2020 2021 2022 2023 2024 2025 2026 Buy and holdMACD
MACD maximum drawdown -72.1% (2020-05-18 → 2025-08-20), prior peak not yet recovered.

Rules of the top strategy

Looks at the gap (MACD) between a short and long average crossing its own signal line.

Method and caveats

Past performance does not guarantee future returns. Parameters were carried forward from the latest full optimization and replayed on this monthly dataset. 0.5% trading costs are included; taxes, slippage and rejected orders are not.
Re-optimize the same period and setupAll asset reports

Read next